Figure 1:

Schematic of select pro and anti-tumor functions of ILC2s in cancer. IL-33-activates ILC2s to produce chemokines that induce NK cells and CD8⁺ T cells to indirectly, and cytokines to directly suppress cancer. In contrast, IL-25 activates ILC2s to produce cytokines that stimulate myeloid cells and eosinophils to promote cancer. MDSC – Myeloid Derived Suppressor Cell; NK – Natural Killer.